26342-05-2 Usage
Description
ETHYL 5-AMINOVALERATE, also known as 5-Aminovaleric acid ethyl ester, is a chemical compound with the molecular formula C7H15NO2. It is an ester of the amino acid 5-aminovaleric acid and ethyl alcohol, known for its pleasant odor and potential physiological and pharmacological effects.
Used in Pharmaceutical Industry:
ETHYL 5-AMINOVALERATE is used as an intermediate in the synthesis of various drugs and medications, contributing to the development of new therapeutic agents.
Used in Flavor and Fragrance Industry:
ETHYL 5-AMINOVALERATE is used as a component in the production of flavors and fragrances, capitalizing on its agreeable scent to enhance consumer products.
Used in Research and Development:
ETHYL 5-AMINOVALERATE is used as a subject of study for its potential role in neurotransmitter modulation and as a therapeutic agent for various health conditions, advancing scientific understanding and potential medical treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 26342-05-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,3,4 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 26342-05:
(7*2)+(6*6)+(5*3)+(4*4)+(3*2)+(2*0)+(1*5)=92
92 % 10 = 2
So 26342-05-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H15NO2/c1-2-10-7(9)5-3-4-6-8/h2-6,8H2,1H3
26342-05-2Relevant articles and documents
Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma
Zhou, Ruolan,Fang, Shaoyu,Zhang, Minmin,Zhang, Qingsen,Hu, Jian,Wang, Mingping,Wang, Chongqing,Zhu, Ju,Shen, Aijun,Chen, Xin,Zheng, Canhui
, p. 349 - 352 (2019)
Multiple myeloma (MM) is the second most common haematological malignancy. Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action. Therefore novel drugs are in urgent need in clinic. Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions. In this study, a series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized. Among them, compounds 7e–7g showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously. They also displayed good growth inhibitory activities against human MM cell line RPMI-8226, which proved their potential value for the treatment of multiple myeloma.
